Briefly, NSCLC or MTC patients who progressed after initial response to selpercatinib or pralsetinib revealed three emerging distinct resistance mutations, namely, G810R/S/C within the RET solvent front, which are associated with impaired binding of selpercatinib and pralsetinib to RET fusions. Here, RET is linked to medullary thyroid gland carcinoma.